Biotech firm Galapagos to wind down cell therapy business
Published by Global Banking & Finance Review®
Posted on October 21, 2025
1 min readLast updated: January 21, 2026

Published by Global Banking & Finance Review®
Posted on October 21, 2025
1 min readLast updated: January 21, 2026

Galapagos will close its cell therapy business, impacting 365 jobs, as it shifts focus to new therapies. Shares fell 14% post-announcement.
AMSTERDAM (Reuters) -Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
The Amsterdam-listed company said it had received several non-binding offers since it began mulling options for its cell therapy business in May, but had concluded that none of those were viable proposals.
Galapagos said it now made more sense to gradually end the cell therapy business and use the capital to build a pipeline of new therapies.
Shares in the company were down 14% in early trading after its announcement.
(Reporting by Bart Meijer; Editing by Jan Harvey)
Corporate strategy refers to the overall plan and direction a company takes to achieve its goals and objectives, including decisions on resource allocation, market positioning, and competitive advantage.
Explore more articles in the Finance category


